Scholarlink

<p>Serum neurofilament light chain (sNfL) reflects neuro‑axonal injury, and is an emerging biomarker in multiple sclerosis (MS). This prospective cross-sectional study compared analytical agreement and clinical applicability among three analytical platforms. Serum samples from adult MS patients were analysed by single molecule array (Simoa) (frozen samples), high-sensitivity ELISA (hsELISA) (frozen samples), and fully automated chemiluminescent immunoassay (CLIA) (fresh and frozen samples). Simoa and hsELISA were strongly correlated (rₛ = 0.796) without systematic bias. CLIA with frozen samples showed higher sNfL levels (relative bias: 39.53% vs. Simoa; 29.56% vs. hsELISA). CLIA with fresh samples correlated very strongly with Simoa (rₛ = 0.820) and strongly with hsELISA (r<sub>s</sub> = 0.764) (relative bias: −7.7% vs. Simoa; −14.3% vs. hsELISA), though broad limits of agreement indicated notable individual variability. Comparison of fresh vs. frozen CLIA values indicated an influence of pre-analytical conditions. Age was positively associated with sNfL determined by Simoa and hsELISA, whereas EDSS correlated only weakly with Simoa-derived sNfL. Simoa and hsELISA yield interchangeable sNfL results with consistent biological correlations, supporting their clinical and research application. CLIA can be automated but is affected by pre-analytical factors. Assay harmonization is essential before routine clinical implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of Simoa, high‑sensitivity ELISA, and CLIA for serum neurofilament light chain quantification in multiple sclerosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Kamila Zondra Revendova,
  • Tereza Schaffartzikova,
  • David Zeman,
  • Pavel Hradilek,
  • Pavlina Kusnierova

摘要

Serum neurofilament light chain (sNfL) reflects neuro‑axonal injury, and is an emerging biomarker in multiple sclerosis (MS). This prospective cross-sectional study compared analytical agreement and clinical applicability among three analytical platforms. Serum samples from adult MS patients were analysed by single molecule array (Simoa) (frozen samples), high-sensitivity ELISA (hsELISA) (frozen samples), and fully automated chemiluminescent immunoassay (CLIA) (fresh and frozen samples). Simoa and hsELISA were strongly correlated (rₛ = 0.796) without systematic bias. CLIA with frozen samples showed higher sNfL levels (relative bias: 39.53% vs. Simoa; 29.56% vs. hsELISA). CLIA with fresh samples correlated very strongly with Simoa (rₛ = 0.820) and strongly with hsELISA (rs = 0.764) (relative bias: −7.7% vs. Simoa; −14.3% vs. hsELISA), though broad limits of agreement indicated notable individual variability. Comparison of fresh vs. frozen CLIA values indicated an influence of pre-analytical conditions. Age was positively associated with sNfL determined by Simoa and hsELISA, whereas EDSS correlated only weakly with Simoa-derived sNfL. Simoa and hsELISA yield interchangeable sNfL results with consistent biological correlations, supporting their clinical and research application. CLIA can be automated but is affected by pre-analytical factors. Assay harmonization is essential before routine clinical implementation.